Dr Sam Moxon has been working on a new grant and exploring how to create a spin out innovation biotech company. This work led him to meet Matthias Alder, who we just had to get on the podcast.

In this show we hear from Gain Therapeutics CEO Matthias Alder. He is leading a biotech company engaged in the development of a potentially disease-modifying therapy for the treatment of neurodegenerative diseases. Hoping to unlock new treatments for difficult to treat disorders with their SEE-Tx™ supercomputer-driven, drug discovery platform targeting allosteric binding sites.

There is a lot of work underway to explore modifying enzymes that have misfolded, losing their functional structure. Misfolding can lead to various diseases, including neurodegenerative disorders like Alzheimer's and Parkinson's. Researchers in this field seek, and Gain Therapeutics study the mechanisms behind enzyme misfolding, explore the consequences of misfolding on cellular functions, and develop strategies to correct or reshape these misfolded enzymes. By gaining insights into this process, scientists hope to discover potential therapeutic interventions for treating diseases associated with misfolded enzymes.

https://www.gaintherapeutics.com/

--

Full biographies on all our guests and a transcript can be found on our website https://www.dementiaresearcher.nihr.ac.uk

--

Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel – https://youtu.be/uVmNbqWKBvM

--

This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.